Abstract
Cardiovascular disease remains the primary cause of mortality for patients with type 2 diabetes, which is characterized by insulin resistance. The thiazolidinediones (TZDs), also known as glitazones, are one of the pharmacological approaches to improve insulin sensitivity. At present, there are two available TZDs: pioglitazone and rosiglitazone. The common target of action for TZDs is the nuclear peroxisome proliferator-activated receptor-γ (PPAR-γ) that regulates the gene transcription involved in adipocyte differentiation and glucose and lipid metabolism. TZDs have shown similar effects on glycemic control, as well as on weight gain, fluid retention, increased risk of heart failure, and leg and forearm fractures. However, TZDs have differential effects on cardiovascular disease. This article will review the differential effects of pioglitazone and rosiglitazone on cardiovascular risk factors and outcomes, as well as the potential differences between them. Based upon available evidence, pioglitazone has a beneficial effect on cardiovascular disease. By contrast, it seems that rosiglitazone increases cardiovascular risk. The difference in lipid profile may be the main factor accounting for the superiority of pioglitazone in reducing cardiovascular risk.
Keywords: T2D, thiazolidinediones, rosiglitazone, pioglitazone, cardiovascular risk
Current Drug Safety
Title: Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Volume: 5 Issue: 3
Author(s): Rafael Simo, Angel Rodriguez and Elena Caveda
Affiliation:
Keywords: T2D, thiazolidinediones, rosiglitazone, pioglitazone, cardiovascular risk
Abstract: Cardiovascular disease remains the primary cause of mortality for patients with type 2 diabetes, which is characterized by insulin resistance. The thiazolidinediones (TZDs), also known as glitazones, are one of the pharmacological approaches to improve insulin sensitivity. At present, there are two available TZDs: pioglitazone and rosiglitazone. The common target of action for TZDs is the nuclear peroxisome proliferator-activated receptor-γ (PPAR-γ) that regulates the gene transcription involved in adipocyte differentiation and glucose and lipid metabolism. TZDs have shown similar effects on glycemic control, as well as on weight gain, fluid retention, increased risk of heart failure, and leg and forearm fractures. However, TZDs have differential effects on cardiovascular disease. This article will review the differential effects of pioglitazone and rosiglitazone on cardiovascular risk factors and outcomes, as well as the potential differences between them. Based upon available evidence, pioglitazone has a beneficial effect on cardiovascular disease. By contrast, it seems that rosiglitazone increases cardiovascular risk. The difference in lipid profile may be the main factor accounting for the superiority of pioglitazone in reducing cardiovascular risk.
Export Options
About this article
Cite this article as:
Simo Rafael, Rodriguez Angel and Caveda Elena, Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698352
DOI https://dx.doi.org/10.2174/157488610791698352 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Etiologic Aspects of Pagets Disease of Bone
Current Rheumatology Reviews Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets From Lizard to Snake; Behind the Evolution of an Extreme Body Plan
Current Genomics Development of Mucoadhesive Buccal Drug Delivery System of Propranolol Hydrochloride Using <i>Aster ericoides</i> Mucilage
Drug Delivery Letters Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology SGLT-2i and Cardiovascular Prognosis
Current Pharmaceutical Design A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation Interplay of Carotenoids with Cigarette Smoking: Implications in Lung Cancer
Current Medicinal Chemistry Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Chemotherapy of Chagas Disease
Current Pharmaceutical Design Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Androgen Deficiency in Aging Male Questionnaire for the Clinical Detection of Testosterone Deficiency in a Population of Black Sub-Saharan African Men with Type 2 Diabetes Mellitus: Is it a Reliable Tool?
Current Diabetes Reviews A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Adeno-Associated Viral Vectors for Retinal Gene Transfer and Treatment of Retinal Diseases
Current Gene Therapy Formulation, Evaluation and Optimization of Self-Nano Emulsifying Drug Delivery System Containing Felodipine
Micro and Nanosystems Editorial (Thematic Issue: Protection, Repair and Regeneration of Achybreaky Heart)
Current Drug Targets